Pulmatrix appoints Amit Munshi to its Board of Directors

– USA, MA – Pulmatrix, Inc. (NASDAQ:PULM), a pharmaceutical company developing innovative inhaled drugs for major lung diseases, has announced the appointment of Amit D. Munshi to the Pulmatrix Board of Directors. Mr. Munshi is currently President and CEO of Arena Pharmaceuticals, a biopharmaceutical company developing small molecule therapeutics across a number of important conditions.

Mr. Munshi has extensive experience in biotechnology and pharmaceuticals with an over 25 year record of accomplishments. Prior to Arena Pharmaceuticals, Mr. Munshi was previously the CEO of Epirus Biopharmaceuticals and held the same role at Percivia LLC (sold to Johnson & Johnson). From 2005 to 2010, Mr. Munshi was the Chief Business Officer and a co-founder of Kythera Biopharmaceuticals, which was later acquired by Allergan for $2.1 billion. Earlier in his career, Mr. Munshi held roles of increasing responsibility at Amgen globally in multiple product management, general management and corporate development positions.

“I am excited to be joining the Board and helping in the Company’s next stage of growth,” said Mr. Munshi. “As a lifelong sufferer of pulmonary disease, I am deeply passionate about the Company’s mission and innovative approach to treating the lungs with the iSPERSE technology.”

“Mr. Munshi brings a breadth of experience in our industry to the table including commercialization of products and business development,” said Pulmatrix CEO Robert W. Clarke, Ph.D. “His previous successes at biotechnology and pharmaceutical companies will broaden the scope of our Board as we move into our next stage of company growth and development of our pipeline programs.”

Mr. Munshi holds multiple undergraduate degrees from the University of California, Riverside, and an MBA from The Peter F. Drucker Graduate School at the Claremont Graduate University. Mr Munshi currently serves on the Board of Cytrellis Biosystems, Inc., a privately held company.

About Pulmatrix

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE technology. The Company’s product pipeline is focused on advancing treatments for lung diseases, including opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) and PUR1900, a proprietary inhaled itraconazole formulation that could benefit severe asthmatics and patients with rare disease like cystic fibrosis. Pulmatrix also has in-licensed a series of novel anti-inflammatory molecules that are in development for COPD (PUR1800) and IPF (PUR5700). Pulmatrix’s product candidates are based on iSPERSE, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

For more information : http://www.pulmatrix.com


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>